Profenso and Vaxxas partner to advance AI vision quality assurance tool for high-density microarray patch manufacturing
Profenso, an Australian Artificial Intelligence (AI) company specialising in advanced automation for regulated industries, today announced a strategic partnership with Australian biotechnology pioneer Vaxxas, to develop a next generation AI vision capability to support quality assurance during high-speed manufacturing of the company’s high-density microarray patch (HD-MAP) technology for vaccination.
Manufactured in an aseptic (sterile) environment, the HD-MAP technology requires precise, stringent controls to ensure every patch meets safety and performance standards.
By integrating Profenso’s AI vision technology into Vaxxas’ production workflows, the collaboration aims to introduce real-time insights, automated quality evaluation and improved traceability across critical manufacturing steps.
Dr Maciej Trzaskowski, Co-Founder and Managing Director of Profenso, said the collaboration highlights Australia’s growing strength in deep tech manufacturing and AI.
“Manufacturing HD-MAP vaccines requires precision at a scale that few technologies demand,” Dr Trzaskowski said. “AI vision systems add value by augmenting human oversight, reducing variability and giving teams richer insight into the production quality essential for highly regulated industries. It’s exciting to be collaborating with Vaxxas on this project to create purpose-built technology that can elevate manufacturing quality on a global scale.”
The project involves Profenso building and training a bespoke AI vision platform, engineered for microscopic scale quality assurance. The solution will combine advanced imaging, agentic architecture and structured quality workflows that integrate with Vaxxas manufacturing controls.
Dr Scott Fry, Chief Operating Officer at Vaxxas, said the partnership represents an important step in advancing the Company’s manufacturing capabilities as it scales its operations for commercial production.
“Ensuring the highest level of manufacturing quality is central to delivering on the promise of HD-MAP technology. Working with Profenso gives us access to leading edge AI innovation tailored for regulated production environments,” Dr Fry said. “Their approach to automated vision analysis will help to strengthen our existing quality processes and support our expansion to larger scale manufacturing.”
The partnership will progress through phased development, with early testing focused on automated classification, surface analysis and microstructure verification. Later stages will explore integration into broader quality management for manufacturing and alignment with future regulatory requirements.
Profenso continues to expand its AI capabilities across the health, government and industrial sectors. Its technology has already been deployed to automate high volume quality and compliance processes at scale.
Vaxxas is currently advancing its HD-MAP technology through clinical studies across multiple disease targets. The company’s platform is designed to improve vaccine performance, simplify logistics and broaden global access to immunisation.
